Maxim analyst Jason McCarthy downgraded Artelo Biosciences (ARTL) to Hold from Buy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
- Artelo Biosciences Reports Increased Losses Amid R&D Investments
- Artelo Biosciences files to sell 899,972 shares of common stock for holders
- Artelo Biosciences Revises Bylaws, Alters Governance Structure
- Artelo Biosciences reports Q3 EPS ($3.97) vs ($2.10) last year
- Artelo Biosciences publishes peer-review article on fatty acid binding proteins